Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/173625
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mesa Gutiérrez, Juan Carlos | - |
dc.contributor.author | Arias Barquet, Lluís | - |
dc.contributor.author | Caminal Mitjana, Josep Maria | - |
dc.contributor.author | Prades Almolda, Sergi | - |
dc.contributor.author | Planas, Núria | - |
dc.contributor.author | Pujol Goita, Octavi | - |
dc.contributor.author | Rubio Caso, Marc | - |
dc.contributor.author | Arruga Ginebreda, Jordi | - |
dc.date.accessioned | 2021-02-03T15:17:35Z | - |
dc.date.available | 2021-02-03T15:17:35Z | - |
dc.date.issued | 2008-12-01 | - |
dc.identifier.issn | 1177-5467 | - |
dc.identifier.uri | http://hdl.handle.net/2445/173625 | - |
dc.description.abstract | Objective: to evaluate efficacy and safety of intravitreal injections of bevacizumab in the treatment of macular edema secondary to retinal vein occlusion (RVO). Methods: prospective study, noncomparative, interventional case series. Twelve consecutive patients (12 eyes) with macular edema associated with nonischemic retinal vein occlusion were treated with intravitreal bevacizumab (1.25 mg). All subjects underwent standardized ophthalmic evaluation at baseline and at weeks 1, 4, 12, and 24, consisting of visual acuity (VA) measurement using ETDRS charts, and imaging with ocular coherence tomography evaluating changes in foveal thickness (FT) and macular volume (MV). Results: the median age was 66 years (± 4.16), and the median duration of symptoms was 4 months (± 1.81). There were six cases of inferior branch vein occlusion and six cases of superior branch retinal vein occlusion. Mean VA improved from 1.32 ± 0.24 (logMAR values) at baseline to 0.8 ± 0.15 (p = 0.0003) at the 6-month follow-up. The macular edema responded promptly, and a trend to restoration of normal macular anatomy was observed at by the seventh day. Mean FT improved from 615.50 ± 116.29 microns to 420 ± 72.53 microns (p = 0.001), and the mean MV improved from 19.81 ± 2.31mm3 to 9.23 ± 1.38 (p = 0.0001) at the 6-month follow-up. | - |
dc.format.extent | 5 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Dove Medical Press | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.2147/opth.s3798 | - |
dc.relation.ispartof | Clinical Ophthalmology, 2008, vol. 2, num. 4, p. 787-791 | - |
dc.relation.uri | https://doi.org/10.2147/opth.s3798 | - |
dc.rights | cc-by-nc (c) Mesa Gutiérrez, Juan Carlos et al., 2008 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Malalties de la retina | - |
dc.subject.classification | Factor de creixement de l'endoteli vascular | - |
dc.subject.classification | Edema | - |
dc.subject.other | Retinal diseases | - |
dc.subject.other | Vascular endothelial growth factors | - |
dc.subject.other | Edema | - |
dc.title | Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 604552 | - |
dc.date.updated | 2021-02-03T15:17:36Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 19668432 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
604552.pdf | 70.17 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License